Advertisement
Screener

EDITAS MEDICINE, INC. (EDIT) Return on Tangible Equity

2.8 / 5 stars · 68/120 Roast Me

Editas Medicine, Inc. Return Tang Equity

Return on tangible equity is the profit a company earns on the physical and financial capital its shareholders own, leaving out goodwill and other intangible assets, shown as a percentage. It is net income divided by tangible equity, which is shareholder equity minus goodwill and intangibles; the table shows both amounts. Because acquired goodwill is removed, it runs higher than ROE for companies that grew by acquisition, and it has no meaning when goodwill exceeds equity. Goodwill and intangibles are taken at the latest reported date on or before each equity date. Quarterly points divide the trailing four quarters of net income by the balance at that quarter end; annual points divide the filed fiscal-year net income by the fiscal-year-end balance.

  • Editas Medicine, Inc. return tang equity for the quarter ending 2026-06-30 was -70.24%, a change of 1164.11% year-over-year.
  • Editas Medicine, Inc. return tang equity for the quarter ending 2026-03-31 was -2471.73%, a change of -2069.25% year-over-year.
  • Editas Medicine, Inc. return tang equity for the quarter ending 2025-12-31 was -586.56%, a change of -409.98% year-over-year.
  • Editas Medicine, Inc. return tang equity for the quarter ending 2025-09-30 was -1485.43%, a change of -1365.54% year-over-year.
  • Editas Medicine, Inc. return tang equity for fiscal 2025 was -586.56%, a change of -409.98% from fiscal 2024.
  • Editas Medicine, Inc. return tang equity for fiscal 2024 was -176.57%, a change of -132.68% from fiscal 2023.
  • Editas Medicine, Inc. return tang equity for fiscal 2023 was -43.89%, a change of 17.23% from fiscal 2022.
  • Editas Medicine, Inc. return tang equity for fiscal 2022 was -61.12%, a change of -26.35% from fiscal 2021.
Available history
2014-12-31 to 2026-06-30
Data captured

Historical Return Tang Equity

DateReturn Tang EquityNet income 12 monthTangible equity
2026-06-30-70.24%-$73.95M$105.28M
2026-03-31-2471.73%-$108.95M$4.41M
2025-12-31-586.56%-$160.06M$27.29M
2025-09-30-1485.43%-$199.84M$13.45M
2025-06-30-1234.35%-$236.86M$19.19M
2025-03-31-402.48%-$251.23M$62.42M
2024-12-31-176.57%-$237.09M$134.27M
2024-09-30-119.89%-$210.57M$175.63M
2024-06-30-83.38%-$193.45M$232.01M
2024-03-31-56.43%-$166.13M$294.4M
2023-12-31-43.89%-$153.22M$349.1M
2023-09-30-54.12%-$195.08M$360.46M
2023-06-30-51.46%-$205.79M$399.92M
2023-03-31-68.97%-$218.95M$317.47M
2022-12-31-61.12%-$220.43M$360.68M
2022-09-30-48.49%-$201.13M$414.75M
2022-06-30-39.64%-$184.49M$465.41M
2022-03-31-36.33%-$186.29M$512.76M
2021-12-31-34.77%-$192.5M$553.64M
2021-09-30-36.40%-$213.57M$586.79M
2021-06-30-27.17%-$166.66M$613.36M
2021-03-31-21.16%-$134.98M$638M
2020-12-31-29.47%-$115.98M$393.59M
2020-09-30-20.68%-$91.25M$441.15M
2020-06-30-30.93%-$132.01M$426.77M
2020-03-31-60.63%-$142.22M$234.57M
2019-12-31-50.96%-$133.75M$262.44M
2019-09-30-57.64%-$121.03M$209.99M
2019-06-30-53.52%-$103.33M$193.06M
2019-03-31-49.85%-$108.27M$217.16M
2018-12-31-46.56%-$109.96M$236.16M
2018-09-30-53.95%-$121.09M$224.45M
2018-06-30-57.26%-$132.45M$231.33M
2018-03-31-48.55%-$120.17M$247.51M
2017-12-31-57.83%-$120.32M$208.08M
2017-09-30-69.47%-$123.51M$177.79M
2017-06-30-63.75%-$117.93M$185M
2017-03-31-53.54%-$110.54M$206.46M
2016-12-31-72.20%-$97.18M$134.61M
2016-09-30-41.39%-$70.44M$170.18M
2016-06-30-30.33%-$56.83M$187.33M
2016-03-31-42.39%-$85.35M$201.36M
2015-12-3187.71%-$72.9M-$83.11M

Annual Return Tang Equity

DateReturn Tang EquityNet income 12 monthTangible equity
2025-12-31-586.56%-$160.06M$27.29M
2024-12-31-176.57%-$237.09M$134.27M
2023-12-31-43.89%-$153.22M$349.1M
2022-12-31-61.12%-$220.43M$360.68M
2021-12-31-34.77%-$192.5M$553.64M
2020-12-31-29.47%-$115.98M$393.59M
2019-12-31-50.96%-$133.75M$262.44M
2018-12-31-46.56%-$109.95M$236.16M
2017-12-31-57.83%-$120.32M$208.08M
2016-12-31-72.20%-$97.18M$134.61M
2015-12-3187.71%-$72.9M-$83.11M
2014-12-3189.49%-$13.69M-$15.29M

Similar stocks

Stock NameCountryMarket CapPE Ratio
Kyverna Therapeutics, Inc. (KYTX)United States$0.434B-3.60
Scribe Therapeutics, Inc. (SCTX)United States$0.410B
Eikon Therapeutics, Inc. (EIKN)United States$0.446B
Zura Bio Ltd (ZURA)$0.398B-6.56
Surrozen, Inc./DE (SRZN)United States$0.395B
AGENUS INC (AGEN)United States$0.383B1.41
Tectonic Therapeutic, Inc. (TECX)United States$0.469B-7.68
C4 Therapeutics, Inc. (CCCC)United States$0.373B-5.65
FENNEC PHARMACEUTICALS INC. (FENC)United States$0.371B-115.85
REGENXBIO Inc. (RGNX)United States$0.477B-3.30